Findings

What do systematic reviews say?

1,361 questions · 1,518 findings · 352 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 73 · 4.8%GRADE not reported 211 · 13.9%Very low 500 · 32.9%Low 411 · 27.1%Moderate 252 · 16.6%High 71 · 4.7%

Intervention not reported

Pain (long term) WOMAC scale from 0 to 20 points (higher is worse pain). · Patients with peripheral joint osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1399 participants
High

Intervention not reported

Function (long term) WOMAC scale from 0 to 68 points (higher is worse function). · Patients with peripheral joint osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1398 participants
High

Intervention not reported

Pain (short term) WOMAC scale from 0 to 20 points (higher is worse pain). · Patients with knee osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1773 participants
Low

Intervention not reported

Function (short term) WOMAC scale from 0 to 68 points (higher is worse function). · Patients with knee osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1767 participants
Low

Intervention not reported

Pain (long term) WOMAC scale from 0 to 20 points (higher is worse pain). · Patients with knee osteoarthritis

1 finding from 1 review

Acupuncture for peripheral joint osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1399 participants
High

Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty

Pain The Hospital for Special Surgrery 100‐point scoring system. Scale from: 0 to 30 (higher is better). · Patients with rheumatoid shoulder

1 finding from 1 review

Surgical interventions for the rheumatoid shoulder 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty

Function The Hospital for Special Surgery 100‐point scoring system. Scale from: 0 to 20 (higher is better). · Patients with rheumatoid shoulder

1 finding from 1 review

Surgical interventions for the rheumatoid shoulder 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Augmented subscapularis transposition vs subscapularis transposition alone during total shoulder arthroplasty

Range of motion The Hospital for Special Surgery 100‐point scoring system . Scale from: 0 to 25 (higher is better). · Patients with rheumatoid shoulder

1 finding from 1 review

Surgical interventions for the rheumatoid shoulder 2010 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Total Shoulder Arthroplasty vs hemiarthroplasty

Disability/Function (ASES) American Shoulder and Elbow Surgeons Shoulder Score. Scale from: 0 to 100 (Higher is better). · patients with Shoulder osteoarthritis

1 finding from 1 review

Surgery for shoulder osteoarthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 88 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to higher global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.32 [1.06, 1.64]
2 studies · 172 participants
Moderate

LOW DOSE (greater than or equal to 2‐<4 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.81 [0.37, 1.75]
2 studies · 173 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: Any reasons ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in leaving the study early: Any reasons ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.78 [0.58, 1.06]
2 studies · 496 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in global state: No clinically important improvement ‐ global… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 0.74 [0.34, 1.58]
1 study · 39 participants
Moderate

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Leaving the study early · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) showed no clear difference in leaving the study early: Any reason ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.04 [0.76, 1.43]
1 study · 459 participants
Moderate

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) vs ANY DOSE ‐ short term

Mental state: No clinically important improvement · patients with schizophrenia

STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) showed no clear difference in mental state: No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.06 [0.83, 1.36]
1 study · 457 participants
Moderate

HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term

Leaving the study early: insufficient response ‐ When compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.28 [0.82, 1.98]
2 studies · 748 participants
Moderate

HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term

Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.18 [0.82, 1.69]
2 studies · 255 participants
Moderate

HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term

Mental state: No clinically important improvement · patients with schizophrenia

HIGH DOSE (greater than or equal to 10 mg/day) leads to higher mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (high certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.24 [1.05, 1.47]
3 studies · 941 participants
High

HIGH DOSE (greater than or equal to 10 mg/day) vs ANY DOSE ‐ short term

Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia

HIGH DOSE (greater than or equal to 10 mg/day) probably leads to higher adverse effects: EPS: unspecified ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.79 [1.01, 3.18]
2 studies · 261 participants
Moderate

ULTRA LOW DOSE (<2 mg/day) vs ANY DOSE ‐ short term

Mental state: No clinically important improvement · patients with schizophrenia

ULTRA LOW DOSE (<2 mg/day) probably leads to higher mental state: 1. No clinically important improvement ‐ as measured… compared with ANY DOSE ‐ short term (moderate certainty).

1 finding from 1 review

Risperidone dose for schizophrenia 2009 · Cochrane Headline outcomes only
RR 1.32 [1.05, 1.66]
1 study · 459 participants
Moderate